Sign In

Denis Azhgirevich

Managing Partner M&A at Nexus Capital

Denis Azhgirevich is an experienced M&A advisory professional currently serving as the Managing Partner M&A at Nexus Capital.1 He specializes in mergers and acquisitions with a primary focus on the Pharma, FMCG, Packaging, and IT sectors.1

Professional Background

Azhgirevich has a strong presence in the pharmaceutical and M&A industries. He regularly shares insights and updates about significant deals and industry trends. For instance, he reported on Eurofarma Laboratórios S.A.'s acquisition of Genfar S.A. from Sanofi for approximately 300 million.3

Contributions and Expertise

As part of his role, Azhgirevich publishes a Pharma M&A Newsletter, providing essential news and analysis in the Russian pharmaceutical industry. He has released editions covering various months, including September and November 2021.45 These newsletters likely offer valuable insights into the current state and future trends of pharmaceutical mergers and acquisitions in Russia.

Career Progression

Azhgirevich's LinkedIn profile indicates that he started his position as Managing Partner at Nexus Capital relatively recently. He has expressed enthusiasm about this new role in his professional journey.26

Through his work and online presence, Denis Azhgirevich demonstrates a deep understanding of the M&A landscape, particularly in the pharmaceutical sector, and continues to be an active voice in the industry.

Highlights

Jul 5 · linkedin

I’m happy to share that I’m starting a new position as Managing Partner at Nexus Capital!

May 10 · linkedin

Essential M&A News in World Pharma for April 2023   Cannabis producer Tilray to buy Hexo for $56 mln https://lnkd.in/egHih5V8   Merck to buy Prometheus Biosciences for about $11 billion https://lnkd.in/eVr3p9z2   Satsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSA https://lnkd.in/eqzCG8mC.   Bankruptcy court approves Intas-Shamrock plan for Unimark Remedies https://lnkd.in/ebBDDZdj.   GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health https://lnkd.in/ehTpS777   CHEPLAPHARM announces acquisition of Zyprexa® from Lilly https://lnkd.in/eXcA7SFJ.   Indian pharma Ipca Labs to buy over 33% stake in Unichem https://lnkd.in/ewh7cJVM).   Quest Diagnostics to Acquire Haystack Oncology, Adding Sensitive Liquid Biopsy Technology for Improving Personalized Cancer Care to Oncology Portfolio https://lnkd.in/eAyAzns5   Assertio picks up Spectrum and its approved drug Rolvedon in $248M-plus deal https://lnkd.in/e4btqPtb.   Astellas Pharma buys Iveric Bio for $5.9 billion https://lnkd.in/egPvUK-h   #april2023 #mergers #mergersandacquisitions #mergersacquisitionsdivestitures #investment  #russia #russiasanctions #divestment #businessexit #multinationalcompanies

Related Questions

What are some of the notable deals Denis Azhgirevich has worked on at Nexus Capital?
How did Denis Azhgirevich start his career in M&A?
What sectors does Denis Azhgirevich focus on at Nexus Capital?
Can you provide more details about the acquisition of Genfar S.A. by Eurofarma Laboratórios S.A?
What makes Denis Azhgirevich an expert in the Pharma and FMCG sectors?
Denis Azhgirevich
Denis Azhgirevich, photo 1
Denis Azhgirevich, photo 2
Add to my network

Location

Moscow, Moscow City, Russia